SEC EDGAR: Government Investigations

Workday Executive Separation Agreement with Carl Eschenbach

Workday, Inc. has entered into an Executive Separation Agreement and General Release of Claims with its former CEO, Carl Eschenbach, effective February 6, 2026. The agreement details separation compensation, including cash severance of $2,625,000 and additional bonus severance of $941,463, along with COBRA payments and equity acceleration.

Astera Labs Transition Services Agreement for CFO Resignation

Astera Labs has entered into a Transition Services Agreement with its Chief Financial Officer, Mike Tate, following his resignation. The agreement outlines his transition from CFO to an employee strategic advisor role from March 2, 2026, to September 1, 2026, with continued salary, benefits, and equity vesting.

Bryan Jones Separation Agreement from Aardvark Therapeutics

Aardvark Therapeutics, Inc. has entered into a separation agreement with Bryan Jones, effective February 9, 2026. Jones will resign from executive officer positions but will serve as CEO of a subsidiary and provide transition services for nine months. The agreement outlines severance benefits contingent on compliance with its terms.

Select Medical Holdings Corporation Announces Q4 2025 Results and 2026 Outlook

Select Medical Holdings Corporation announced its financial results for the fourth quarter and full year ended December 31, 2025, along with its 2026 business outlook and a cash dividend declaration. The company reported increased revenue for both periods and significant improvements in income from continuing operations compared to the prior year.

Semnur Pharmaceuticals - Jaisim Shah Separation Agreement

Semnur Pharmaceuticals has filed a separation agreement with Jaisim Shah, detailing the terms of his departure as an employee and director. The agreement outlines continued base salary payments for six months and a 90-day extension to exercise vested stock options.